Designation of Mercaptopurine as an Orphan Drug - Ballia Holdings Pty Ltd

Overview

The Designation of Mercaptopurine as an Orphan Drug 2013, enacted on 14 December 2012, addresses the need for incentivising the development and availability of treatments for rare conditions that affect a small patient population. The Therapeutic Goods Administration, acting under the authority granted by the Therapeutic Goods Act 1989, designated Mercaptopurine as an orphan drug for the treatment of Acute Lymphoblastic Leukaemia in children. This action aims to encourage the research, development, and availability of orphan drugs by providing certain benefits such as streamlined regulatory processes and market exclusivity. The policy objective behind this designation is to ensure that life-saving treatments are developed and accessible for those affected by rare diseases, thereby improving health outcomes for a vulnerable patient demographic.

Scope and Application

The designation of Mercaptopurine as an orphan drug under the Therapeutic Goods Regulations 1990 pertains specifically to the treatment of Acute Lymphoblastic Leukaemia in children, with the designated form being an oral suspension. This designation applies to the therapeutic agent Mercaptopurine, which is sponsored by Ballia Holdings Pty Ltd. The application of this legislation is directed towards the medical and pharmaceutical sectors, targeting a very specific demographic of patients, namely children suffering from Acute Lymphoblastic Leukaemia. The scope of the legislation is primarily within the Commonwealth jurisdiction, as it falls under the purview of the Therapeutic Goods Administration and its regulations. There are no stated exclusions or exemptions in this particular designation, though the broader legislative framework may include provisions that apply to other drugs and therapeutic goods. Any further extension or restriction of this application is subject to subordinate instruments and amendments within the Therapeutic Goods Regulations.

Key Provisions

The main operative section of the legislation, section 16J of the Therapeutic Goods Regulations 1990, empowers the delegate of the Secretary to designate a drug as an orphan drug, which in this case is Mercaptopurine for the treatment of Acute Lymphoblastic Leukaemia in children. This designation was formally announced on 14 December 2012, with the drug's dose form specified as an oral suspension. This action is intended to encourage the research, development, and availability of treatments for rare diseases that affect a small number of people. The legislation imposes specific obligations on the parties involved, primarily the sponsor, which in this case is Ballia Holdings Pty Ltd. The sponsor is responsible for ensuring that the designated orphan drug meets the necessary quality, safety, and efficacy standards set by the Therapeutic Goods Administration (TGA). The designation of Mercaptopurine as an orphan drug likely involves additional regulatory benefits for the sponsor, such as streamlined approval processes, financial incentives, and potential market exclusivity. These provisions are intended to mitigate the risks and costs associated with developing treatments for rare diseases. There are no explicit offences, penalties, or civil or criminal consequences detailed within the text of this legislation for breaches related to the orphan drug designation. However, failure to comply with the broader requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 could result in significant regulatory action by the TGA. Potential penalties for non-compliance with these overarching regulations can include fines, product recalls, and legal action. For example, section 37 of the Therapeutic Goods Act 1989 allows for substantial penalties, including fines of up to $1,260,000 for corporations and $252,000 for individuals, for serious and repeated breaches of the Act. These broader provisions ensure that all parties adhere to the stringent standards required for the safe and effective use of therapeutic goods in Australia.